Mark J. Mulligan
A5064116200- SARS-CoV-2 and COVID-19 Research
- HIV Research and Treatment
- COVID-19 Clinical Research Studies
- Influenza Virus Research Studies
- Immunotherapy and Immune Responses
- Mosquito-borne diseases and control
- vaccines and immunoinformatics approaches
- Vaccine Coverage and Hesitancy
- SARS-CoV-2 detection and testing
- HIV/AIDS Research and Interventions
- Viral Infections and Vectors
- Virology and Viral Diseases
- Herpesvirus Infections and Treatments
- Immune Cell Function and Interaction
- Animal Virus Infections Studies
- Poxvirus research and outbreaks
- Respiratory viral infections research
- Viral Infections and Outbreaks Research
- T-cell and B-cell Immunology
- Hepatitis B Virus Studies
- Viral gastroenteritis research and epidemiology
- Immune Response and Inflammation
- Long-Term Effects of COVID-19
- Bacillus and Francisella bacterial research
- Virus-based gene therapy research
New York University
2018-2025
Emory University
2015-2024
HOPE Clinic
2015-2024
NYU Langone Health
2019-2023
Manhattan Psychiatric Center
2023
VA Palo Alto Health Care System
2022
New York Proton Center
2021-2022
University of Rochester
2021
Unity Health System
2021
Columbia University
2021
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the resulting disease, disease 2019 (Covid-19), have spread to millions of persons worldwide. Multiple vaccine candidates are under development, but no is currently available. Interim safety immunogenicity data about candidate BNT162b1 in younger adults been reported previously from trials Germany United States.In an ongoing, placebo-controlled, observer-blinded, dose-escalation, phase 1 trial conducted States, we...
In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome 2 (SARS-CoV-2)1, a pandemic. With rapidly accumulating numbers of cases and deaths reported globally2, vaccine urgently needed. Here we report available safety, tolerability immunogenicity data from an ongoing placebo-controlled, observer-blinded dose-escalation study (ClinicalTrials.gov identifier NCT04368728) among 45 healthy adults (18–55...
The 2009 pandemic H1N1 influenza demonstrated the global health threat of reassortant strains. Herein, we report a detailed analysis plasmablast and monoclonal antibody responses induced by infection in humans. Unlike antibodies elicited annual vaccinations, most neutralizing were broadly cross-reactive against epitopes hemagglutinin (HA) stalk head domain multiple from cells that had undergone extensive affinity maturation. Based on these observations, postulate plasmablasts producing...
Significance In this study, we address the issue of cross-reactivity between dengue virus (DENV) and Zika (ZIKV) by testing sera plasmablast-derived monoclonal antibodies from patients against ZIKV. We show that both acute convalescent potently bind neutralize ZIKV is also evident at level. demonstrate in vitro antibody-dependent enhancement infection presence dengue-induced antibodies. Our findings strongly suggest preexisting may modulate immune responses to infection. These data are...
A safe and effective vaccine for the prevention of human immunodeficiency virus type 1 (HIV-1) infection is a global priority. We tested efficacy DNA prime-recombinant adenovirus 5 boost (DNA/rAd5) regimen in persons at increased risk HIV-1 United States.
Although the three vaccines against coronavirus disease 2019 (Covid-19) that have received emergency use authorization in United States are highly effective, breakthrough infections occurring. Data needed on serial of homologous boosters (same as primary vaccine) and heterologous (different from fully vaccinated recipients.In this phase 1-2, open-label clinical trial conducted at 10 sites States, adults who had completed a Covid-19 vaccine regimen least 12 weeks earlier no reported history...
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies key class of therapeutics that may bridge widespread vaccination campaigns offer treatment solution in populations less responsive to vaccination. Here, we report high-throughput microfluidic screening antigen-specific B cells led the identification LY-CoV555 (also known as bamlanivimab), potent anti-spike...
We have previously shown that broadly neutralizing antibodies reactive to the conserved stem region of influenza virus hemagglutinin (HA) were generated in people infected with 2009 pandemic H1N1 strain. Such are rarely seen humans following infection or vaccination seasonal strains. However, important question remained whether inactivated vaccine, like infection, could also induce these antibodies. To address this question, we analyzed B-cell responses 24 healthy adults immunized vaccine...
BackgroundThe safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection United States, Chile, Peru has not been known.MethodsIn this ongoing, double-blind, randomized, placebo-controlled, phase 3 clinical trial, we investigated safety, efficacy, immunogenicity two doses as compared with placebo preventing onset symptomatic disease 2019 (Covid-19) 15 days or more...
The live yellow fever vaccine (YF-17D) offers a unique opportunity to study memory CD8(+) T cell differentiation in humans following an acute viral infection. We have performed comprehensive analysis of the virus-specific response using overlapping peptides spanning entire genome. Our results showed that YF-17D induces broad targeting several epitopes within each protein. identified dominant HLA-A2-restricted epitope NS4B protein and used tetramers specific for this track over 2 year period....
Systems approaches have been used to describe molecular signatures driving immunity influenza vaccination in humans. Whether such are similar across multiple seasons and diverse populations is unknown. We applied systems study immune responses young, elderly, diabetic subjects vaccinated with the seasonal vaccine five consecutive seasons. Signatures of innate plasmablasts correlated predicted antibody titers at 1 month after >80% accuracy but were not associated longevity response. Baseline...
The Zika virus epidemic and associated congenital infections have prompted rapid vaccine development. We assessed two new DNA vaccines expressing premembrane envelope structural proteins.We did phase 1, randomised, open-label trials involving healthy adult volunteers. VRC 319 trial, done in three centres, plasmid VRC5288 (Zika Japanese encephalitis chimera), the 320, one centre, VRC5283 (wild-type virus). Eligible participants were aged 18-35 years VRC19 18-50 320. Participants randomly...
To investigate the humoral and cellular immune response to messenger RNA (mRNA) COVID-19 vaccines in patients with immune-mediated inflammatory diseases (IMIDs) on immunomodulatory treatment.
Background The reasons for black/white disparities in HIV epidemics among men who have sex with puzzled researchers decades. Understanding these requires looking beyond individual-level behavioral risk to a more comprehensive framework. Methods and Findings From July 2010-Decemeber 2012, 803 (454 black, 349 white) were recruited through venue-based online sampling; consenting provided STI testing, completed survey partner inventory, place of residence geocoding. prevalence was higher black...
Significance Vaccination is the most effective means of attaining protection against influenza viruses. However, constantly evolving nature viruses enables them to escape preexisting immune surveillance, and thus thwarts public health efforts control annual epidemics occasional pandemics. One solution elicit antibodies directed highly conserved epitopes, such as those within stem region HA, principal target virus-neutralizing antibody responses. This study shows that vaccines induce...
Background. The current West Africa Ebola virus disease (EVD) outbreak has resulted in multiple individuals being medically evacuated to other countries for clinical management.